行情

RMTI

RMTI

罗克韦尔医药
NASDAQ

实时行情|Nasdaq Last Sale

0.6380
0.0000
0.00%
交易中 11:52 09/24 EDT
开盘
0.6444
昨收
0.6380
最高
0.6444
最低
0.6200
成交量
11.07万
成交额
--
52周最高
1.980
52周最低
0.5590
市值
5,990.11万
市盈率(TTM)
-1.7370
分时
5日
1月
3月
1年
5年
Rockwell Medical, Inc. 将出席 HC Wainwright 第 23 届年度全球投资大会
WIXOM, Mich., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today...
GlobeNewswire · 09/09 13:52
HC Wainwright & Co. 维持对 Rockwell Medical 的买入,将目标价下调至 5 美元
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rockwell Medical (NASDAQ:RMTI) with a Buy and lowers the price target from $5.5 to $5.
Benzinga · 09/07 10:18
--HC Wainwright 将 Rockwell Medical 的目标价格从 5.50 美元上调至 5 美元,维持买入评级
MT Newswires · 09/07 09:15
Rockwell Medical, Inc. 宣布根据纳斯达克上市规则 5635(C)(4) 进行诱导授予
Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced ...
GlobeNewswire · 08/19 20:00
The Daily Biotech Pulse:AzurRx 关注数据,Agios 的 Mitapivat 监管申请获得优先审查接受,FDA 批准葛兰素史克
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse:礼来重组神经科学业务部门,Helius Medical 获得突破性指定,Ra Medical 出售皮肤科业务
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
回顾:罗克韦尔医疗第二季度收益
Shares of Rockwell Medical (NASDAQ:RMTI) fell 12.6% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 0.00% over the past year to ($0.09), which missed the estimate of ($0.08).
Benzinga · 08/16 20:45
Rockwell Medical Q2 每股收益 $(0.09) 低于 $(0.08) 估计,销售额为 1514 万美元 低于 1821 万美元估计
Rockwell Medical (NASDAQ:RMTI) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is unchanged from the same period last year. The company
Benzinga · 08/16 20:37
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解RMTI最新的财务预测,通过RMTI每股收益,每股净资产,每股现金流等数据分析罗克韦尔医药近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测RMTI价格均价为5.00,最高价位5.00,最低价为5.00。
EPS
机构持股
总机构数: 131
机构持股: 2,068.65万
持股比例: 22.03%
总股本: 9,388.89万
类型机构数股数
增持
13
92.55万
建仓
12
321.42万
减持
27
867.59万
平仓
24
82.76万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.69%
制药与医学研究
-0.86%
高管信息
Non-Executive Chairman/Independent Director
John McLaughlin
President/Chief Executive Officer/Director
Russell Ellison
Chief Financial Officer/Executive Vice President
Russell Skibsted
Chief Accounting Officer/Vice President/Controller
Paul McGarry
Vice President - Operations
Michael DeYoung
Other
Marc Hoffman
Other
Raymond Pratt
Independent Director
John Cooper
Independent Director
Allen Nissenson
Independent Director
Robert Radie
Independent Director
Mark Ravich
Independent Director
Andrea Smiley
暂无数据
RMTI 简况
Rockwell Medical Inc是一家生物制药公司。该公司专注于晚期肾脏疾病和慢性肾脏疾病,其产品用于治疗缺铁和血液透析。该公司同时也为透析供应商和分销商生产血液透析浓缩液。该公司的肾脏药物治疗方法Triferic,对疾病管理初期有作用。Triferic的目的是在每次透析治疗时,通过透析液来替换血液透析病人的铁,同时维持血红蛋白。该公司已经开发了多种配方的Triferic治疗方法:透析液Triferic和静脉内Triferic(I.V. Triferic)。透析液Triferic是用于替换铁和维持血液透析病人血红蛋白的治疗方法。

微牛提供Rockwell Medical Inc(NASDAQ-RMTI)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的RMTI股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易RMTI股票基本功能。